Ogkologos | Ogkologos.com | Page 46

Home Authors Posts by Ogkologos

4396 POSTS 0 COMMENTS

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for...

Ogkologos - July 8, 2025

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS...

Ogkologos - July 7, 2025

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO...

Ogkologos - July 4, 2025

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step...

Ogkologos - July 4, 2025

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

Ogkologos - July 4, 2025

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

Ogkologos - July 3, 2025

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive...

Ogkologos - July 2, 2025

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of...

Ogkologos - July 1, 2025

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with...

Ogkologos - July 1, 2025

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

Ogkologos - June 30, 2025

1...454647...440 Page 46 of 440

MOST POPULAR

Program Helps Medically Underserved, Minority Cancer Survivors Be More Active

July 3, 2024

The most important cancer research stories of 2022

December 14, 2022

FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes

July 14, 2020

Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in...

June 8, 2026

HOT NEWS

FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease

How does processed and red meat cause cancer and how much...

Researchers Find a Way to Prevent Cancer Cells from Taking in...

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer